Harpoon Therapeutics announced that AbbVie has offered a unique licensing opportunity for its HPN217 program, targeting BCMA, as per their Development and Option Agreement.

Vincerx Pharma, Inc. declared that the initial patient in the Phase 1 clinical trial has received treatment with VIP943.

Oscotec Inc. and ADEL Inc. has announced that the FDA has given the IND application approval for ADEL-Y01 to be used in the treatment of Alzheimer's Disease.

Nektar Therapeutics disclosed fresh clinical results concerning rezpegaldesleukin utilised for patients battling atopic dermatitis, featuring new clinical effectiveness parameters from its Phase 1b research.

Coeptis Therapeutics delivers an update on the safety and dosage from Phase 1 Trials of DVX201, intended for those with Relapsed/Refractory AML or High Risk MDS.

Alzheon, Inc. reported that their Phase 2 study of ALZ-801 resulted in reduced neural degradation, stabilized brain function, and improved cognition in initial Alzheimer's patients with the apolipoprotein ε4 allele over two years of treatment.

IQ32 Bio and Horizon Therapeutics initiated a Phase 2 trial for bempikibart's effectiveness against severe adult alopecia areata.

At the 2023 IASLC World Lung Cancer Conference in Singapore, RS Oncology shared a first-of-its-kind PRX3 inhibitor, RSO-021's potential to combat swift mesothelioma tumor progression.

InnoCare Pharma announced that it received IND approval for a Chinese clinical trial to study the effects of new SHP2 allosteric inhibitor, ICP-189.

Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.

NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.

Myeloid Therapeutics, a clinical-stage cancer treatment company, has given the first dose of MT-302 to a patient in a Phase 1 trial for advanced or metastatic epithelial tumors.